Skip to main content
Clinical Trials/NCT04659291
NCT04659291
Recruiting
Not Applicable

Prospective Study on Patients With Obstructive Sleep Apnea in Hong Kong (PrOSA)

Chinese University of Hong Kong1 site in 1 country1,000 target enrollmentAugust 30, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obstructive Sleep Apnea
Sponsor
Chinese University of Hong Kong
Enrollment
1000
Locations
1
Primary Endpoint
incidence of Cardiovascular disease
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Obstructive sleep apnea syndrome (OSAS) is a common disorder with prevalence rates of at least 4% among the middle-aged male Caucasians and Hong Kong (HK) Chinese populations. It is characterized by repetitive episodes of upper airway obstruction, causing intermittent hypoxia, sleep fragmentation, disabling daytime sleepiness, impaired cognitive function and poor health status. OSAS patients are at increased risks of non-fatal and fatal cardiovascular morbidity and mortality including sudden death, in addition to being more prone to road traffic accidents. However, there is no long term follow up of patients with OSAS on the incidence of cardiovascular disease, compliance on the therapy and the impact of the quality of life. The study is aimed to carry out a prospective observational study assessing the role of OSAS as a possible cause of increased cardiovascular risk and cognitive decline.

Registry
clinicaltrials.gov
Start Date
August 30, 2020
End Date
August 29, 2028
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Susanna SS Ng

Assistant Professor

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • suspected obstructive sleep apnea syndrome
  • aged 18 or above
  • must be able to speak, read and understand Chinese or English
  • possess the ability to respond to questions and follow instructions.

Exclusion Criteria

  • already treated sleep apnea,
  • a limited life expectancy due to illness unrelated to sleep apnea
  • human immunodeficiency virus (HIV),
  • advanced renal disease,
  • uncontrolled malignancies
  • documented alcohol or drug abuse up to 1 year prior to inclusion in the study.

Outcomes

Primary Outcomes

incidence of Cardiovascular disease

Time Frame: 5 years

Secondary Outcomes

  • Change of Epworth Sleepiness Score(5 years)
  • Change of Montreal Cognitive Assessment score (MoCA)(5 years)

Study Sites (1)

Loading locations...

Similar Trials